Jean Costentin, MD

laboratoire de neuropsychopharmacologie expérimentale Université de Rouen 
"Jean Costentin"
Mean distance: 18.05 (cluster 11)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Costentin J. (2015) [Neurobiology of endocannabinoids and central effects of tetrahydrocannabinol contained in indian hemp]. Bulletin De L'AcadéMie Nationale De MéDecine. 198: 527-38; discussion 5
Pelloux Y, Costentin J, Duterte-Boucher D. (2015) Differential involvement of anxiety and novelty preference levels on oral ethanol consumption in rats. Psychopharmacology. 232: 2711-21
Viana AF, Costentin J, do Rego JC, et al. (2015) G-protein activation revealed by [35S]-GTPγS binding assay is involved on the antidepressant-like effect of Hypericum caprifoliatum and Hypericum polyanthemum cyclohexane extracts Brazilian Journal of Pharmacognosy. 25: 387-394
Le Maître E, Dourmap N, Vilpoux C, et al. (2013) Acute and subchronic treatments with selective serotonin reuptake inhibitors increase Nociceptin/Orphanin FQ (NOP) receptor density in the rat dorsal raphe nucleus; interactions between nociceptin/NOP system and serotonin. Brain Research. 1520: 51-60
Neveu C, Lefranc B, Tasseau O, et al. (2012) Rational design of a low molecular weight, stable, potent, and long-lasting GPR103 aza-β3-pseudopeptide agonist. Journal of Medicinal Chemistry. 55: 7516-24
Billet F, Costentin J, Dourmap N. (2012) Influence of corticostriatal δ-opioid receptors on abnormal involuntary movements induced by L-DOPA in hemiparkinsonian rats. Experimental Neurology. 236: 339-50
Stein AC, Viana AF, Müller LG, et al. (2012) Uliginosin B, a phloroglucinol derivative from Hypericum polyanthemum: a promising new molecular pattern for the development of antidepressant drugs. Behavioural Brain Research. 228: 66-73
Cravezic A, Fichna J, Gach K, et al. (2011) Effect of potent endomorphin degradation blockers on analgesic and antidepressant-like responses in mice. Neuropharmacology. 61: 1229-38
Costentin J. (2009) [A new approach to antischizophrenic therapeutics: D2 dopamine receptor partial agonists]. Annales Pharmaceutiques Franã§Aises. 67: 310-9
Bohn P, Le Fur N, Hagues G, et al. (2009) Rational design of central selective acetylcholinesterase inhibitors by means of a "bio-oxidisable prodrug" strategy. Organic & Biomolecular Chemistry. 7: 2612-8
See more...